We serve Chemical Name:2,3-Difluoro-4-(phenoxymethyl)benzaldehyde CAS:947279-29-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3-Difluoro-4-(phenoxymethyl)benzaldehyde
CAS.NO:947279-29-0
Synonyms:2,3-Difluoro-4-(phenoxymethyl)benzaldehyde
Molecular Formula:C14H10F2O2
Molecular Weight:248.22500
HS Code:2913000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:26.30000
Exact Mass:248.06500
LogP:3.35630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,3-Difluoro-4-(phenoxymethyl)benzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-Difluoro-4-(phenoxymethyl)benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-Difluoro-4-(phenoxymethyl)benzaldehyde Use and application,2,3-Difluoro-4-(phenoxymethyl)benzaldehyde technical grade,usp/ep/jp grade.
Related News: US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 2,3-Difluoro-4-(phenoxymethyl)benzaldehyde manufacturer Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. 2,3-Difluoro-4-(phenoxymethyl)benzaldehyde supplier All of China��s provinces and territories have now been touched by the outbreak. 2,3-Difluoro-4-(phenoxymethyl)benzaldehyde vendor Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. 2,3-Difluoro-4-(phenoxymethyl)benzaldehyde factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
